A Phase 2 interventional study of GSK1349572 and efavirenz in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 35 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-16.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
This Phase IIb study in HIV-infected antiretroviral naive adult subjects will include a dose-ranging evaluation of GSK1349572 10mg, 25mg and 50mg once daily blinded doses and a control arm of open label efavirenz 600mg once daily. Background ART for all study subjects will be chosen by the investigators and will be either Truvada or Epzicom/Kivexa. Data from the three doses of GSK1349572 will be compared on the basis of antiviral activity, safety/tolerability and pharmacokinetics over 16-24 weeks.
Several planned interim analyses will evaluate data in real time; any doses considered inferior will be dropped and subjects on those doses of GSK1349572 will have the option to switch to either the highest dose still under investigation or the selected dose. Subjects will be able to remain in the study, unless they reach a stopping criterion, for at least 96 weeks.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 208 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Subjects starting abacavir as part of the NRTI backbone must have been screened and be negative for the HLA-B*5701 allele.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects will receive GSK1349572 10mg once daily blinded to dose
Drug: GSK1349572
subjects will receive GSK1349572 25mg once daily blinded to dose
Drug: GSK1349572
subjects will receive GSK1349572 50mg once daily blinded to dose
Drug: GSK1349572
efavirenz will serve as the internal control arm
Drug: efavirenz
investigational HIV-1 integrase inhibitor
approved therapy for HIV-1 infection, used as an internal study control
Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16
Plasma samples were collected for quantitative HIV-1 RNA analysis at Week 16. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason. Data are reported per the Week 16 report. In later cuts of the data, the Week 16 values may have changed (because of the nature of the TLOVR algorithm).ITT-E Population included all randomized participants who received at least one dose of study medication
Time frame: Week 16
Viral Change Over the Initial 2 Weeks of Treatment
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline and Week 2. Viral change is defined as the change in plasma HIV-1 RNA over the initial 2 weeks of treatment, calculated as the value at Week 2 minus the value at Baseline. Only those participants available at the specified time point were analyzed.
Time frame: Baseline and Week 2
Change From Baseline in HIV-1 RNA at the Indicated Time Points
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at the Indicated Time Points
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT-E Population.
Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Number of Participants With New HIV-associated Conditions of the Indicated Class
HIV-associated conditions were assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the acquired immunodeficiency syndrome (AIDS) surveillance case definition.
Time frame: From Baseline up to Week 96
Number of Participants With the Indicated Type of HIV-1 Disease Progression (AIDS or Death)
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CAT A at Baseline (BS) to CAT B event (EV), CAT A at BS to a CAT C EV; CAT B at BS to a CAT C EV; CAT C at BS to a new CAT C EV; or CAT A, B, or C at BS to death.
Time frame: From Baseline up to Week 96
Number of Participants With Plasma HIV-1 RNA <50 c/mL
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.
Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Number of Participants With Plasma HIV-1 RNA <400 c/mL
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<400 c/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.
Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Events (SAE)
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. All clinically suspected cases of hypersensitivity reaction to abacavir in participants receiving abacavir/lamivudine were reported as SAEs. Medical or scientific judgment was to have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold \>=3%) and SAEs.
Time frame: From Baseline up to Week 96/Early Withdrawal
Number of Participants With the Indicated Grade 1 to Grade 4 Treatment-emergent Clinical Chemistry and Hematology Toxicities
Blood samples were collected for the measurement of clinical chemistry and hematology parameters. Toxicities were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
Time frame: From Baseline up to Week 96/Early Withdrawal
Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Genotypic Resistance Population: all participants in the ITT-E Population with available on-treatment genotypic data, excluding participants who were not protocol-defined virologic failures.
Time frame: From Baseline up to Week 96/Early Withdrawal
Number of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.
Time frame: From Baseline up to Week 96/Early Withdrawal
Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) at the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance
The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. Fold increase in DTG FC at the time of PDVF was derived as the PDVF FC/Baseline FC ratio. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Phenotypic Resistance Population: all participants in the ITT-E Population with available on-treatment phenotypic data
Time frame: From Baseline up to Week 96/Early Withdrawal
Plasma DTG Concentration
Blood samples for the determination of plasma DTG concentration were collected from the participants randomized to receive DTG, at the following time points: pre-dose and 2-4 hours post-dose at Weeks 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. The Pharmacokinetic (PK) Summary Population is comprised of all participants who received DTG and underwent intensive PK sampling or limited PK sampling during the study and provided evaluable DTG PK parameters. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles).Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.
Time frame: Week 2, Week 12, and Week 24
AUC(0-tau) of DTG
The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed.
Time frame: Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2
Maximal Concentration (Cmax), Minimal Concentration (Cmin), and Concentration at the End of Dosing Interval (Ctau) of DTG
The Cmax, Cmax, and Ctau of DTG were determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.
Time frame: Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2
Pre-dose Concentration (C0) and C0 Avg of DTG
The plasma DTG C0 of DTG was determined using limited/sparse PK sampling at Week 2, Week 12, and Week 24. C0 avg was calculated at Week 24 as the mean of the C0 of DTG at Week 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.
Time frame: Week 2, Week 12, and Week 24
Time to Maximal Drug Concentration (Tmax) of DTG
Tmax of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.
Time frame: Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2
Relationship Between the Change From Baseline in Plasma HIV-1 RNA at Week 2 and the Indicated Plasma DTG PK Parameters
Relationships between Week 2 plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in plasma HIV-1 RNA at Week 2 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between plasma HIV-1 RNA and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. PK/Pharmacodynamic (PD) Analysis Population: all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable DTG plasma concentration data considered suitable for investigation of relationship with the PD measures
Time frame: Week 2
Relationship Between the Change From Baseline in CD4+ Cell Counts at Week 96 and the Indicated Plasma DTG PK Parameters
Relationships between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], C0avg \[average pre-dose concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in CD4+ cell counts at Week 96 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between CD4+ cell counts and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association.Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.Only those participants available at the specified time points were analyzed (represented by n=X in the category titles)
Time frame: Week 96
Relationship Between the Indicated Safety Parameters at Week 96 and the Indicated Plasma DTG PK Parameters
Relationships between log-transformed plasma DTG PK parameters (AUC\[0-tau\], Cmax, C0, C0avg, Ctau, and Cmin) and safety parameters (AE occurrence, maximum AE intensity, alanine aminotransferase \[ALT\], change from Baseline \[CFB\] in ALT, total bilirubin, CFB in total bilirubin, creatine kinase, CFB in creatine kinase, triglycerides, CFB in triglycerides, lipase, CFB in lipase, total cholesterol \[TC\], CFB in TC) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between safety parameters and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. The presence of \>=1 AE was used for AE occurrence. The most severe AE grade/intensity was used for maximum AE intensity. Maximum laboratory values per participant were used for safety parameters. CFB was calculated as the post-Baseline value minus the value at Baseline.
Time frame: Week 96
Relationship Between Gastrointestinal System Organ Class AEs of Special Interest at Week 96 and the Indicated Plasma DTG PK Parameters
Logistic regressions were performed to examine the correlation between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], Ctau \[concentration at the end of the dosing interval\], and C0avg \[average pre-dose concentration\]) on log scales and the presence of gastrointestinal system organ class AEs (abdominal pain, diarrhea, nausea, and vomiting) at Week 96. Data are presented as estimates from logistic regression, which is a measure of the association between AEs of special interest and plasma DTG PK parameters. A value of 0 indicates no statistical association; a large absolute value of the estimate indicates higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Results are presented for participants in any DTG group (overall DTG).Only those participants available at the specified time points were analyzed represented by n=X in the category titles
Time frame: Week 96
Change From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at the Indicated Time Points
Change from Baseline in CD8+ cell count data are not available; CD8+ data are only listed on a per-participant basis and were not summarized.
Time frame: Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96
Randomization Phase participants received Dolutegravir (DTG 10, 25 or 50 milligrams\[mg\]) with Placebo/Efavirenz (EFV) for 96 Weeks . DTG participants who completed 96 Weeks continued or were switched to receive DTG 50 mg in Open label phase until DTG was locally available.
| Milestone | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Open-label DTG 50 mg QD |
|---|---|---|---|---|---|
| Started | 53 | 51 | 51 | 50 | 0 |
| Completed | 48 | 44 | 46 | 40 | 0 |
| Not completed | 5 | 7 | 5 | 10 | 0 |
| Withdrew: Adverse event | 1 | 1 | 2 | 5 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Protocol-defined stopping criteria | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 2 | 0 |
| Milestone | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Open-label DTG 50 mg QD |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 138 |
| Completed | 0 | 0 | 0 | 0 | 88 |
| Not completed | 0 | 0 | 0 | 0 | 50 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 12 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 12 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 14 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 8 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Week 16. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason. Data are reported per the Week 16 report. In later cuts of the data, the Week 16 values may have changed (because of the nature of the TLOVR algorithm).ITT-E Population included all randomized participants who received at least one dose of study medication
| participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16 | 51 | 47 | 46 | 29 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline and Week 2. Viral change is defined as the change in plasma HIV-1 RNA over the initial 2 weeks of treatment, calculated as the value at Week 2 minus the value at Baseline. Only those participants available at the specified time point were analyzed.
| Log10 c/mL | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Viral Change Over the Initial 2 Weeks of Treatment | -2.387 ± 0.4595 | -2.365 ± 0.5458 | -2.392 ± 0.4241 | -1.930 ± 0.4312 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
| Log10 c/mL | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Week 1, n=53, 50, 48, 50 | -1.815 ± 0.3999 | -1.773 ± 0.4650 | -1.738 ± 0.3840 | -1.562 ± 0.4158 |
| Week 2, n=53, 50, 50, 48 | -2.387 ± 0.4595 | -2.365 ± 0.5458 | -2.392 ± 0.4241 | -1.930 ± 0.4312 |
| Week 4, n=53, 50, 50, 45 | -2.629 ± 0.5863 | -2.583 ± 0.6337 | -2.713 ± 0.5471 | -2.162 ± 0.5400 |
| Week 8, n=52, 50, 49, 45 | -2.657 ± 0.6980 | -2.666 ± 0.6667 | -2.848 ± 0.6556 | -2.450 ± 0.5989 |
| Week 12, n=53, 49, 49, 45 | -2.685 ± 0.6831 | -2.671 ± 0.6850 | -2.860 ± 0.6772 | -2.603 ± 0.5869 |
| Week 16, n=52, 49, 49, 45 | -2.718 ± 0.6593 | -2.668 ± 0.6826 | -2.859 ± 0.6876 | -2.698 ± 0.6715 |
| Week 20, n=52, 48, 49, 44 | -2.701 ± 0.6423 | -2.662 ± 0.6908 | -2.869 ± 0.6896 | -2.745 ± 0.6602 |
| Week 24, n=52, 49, 48, 45 | -2.700 ± 0.6261 | -2.657 ± 0.6969 | -2.853 ± 0.6889 | -2.773 ± 0.7026 |
| Week 32, n=52, 49, 47, 45 | -2.717 ± 0.6588 | -2.658 ± 0.6991 | -2.855 ± 0.6963 | -2.772 ± 0.7021 |
| Week 40, n=51, 48, 47, 44 | -2.647 ± 0.7039 | -2.665 ± 0.7051 | -2.855 ± 0.6934 | -2.795 ± 0.7169 |
| Week 48, n=51, 48, 48, 45 | -2.723 ± 0.6519 | -2.667 ± 0.6934 | -2.850 ± 0.6849 | -2.711 ± 0.7765 |
| Week 60, n=50, 48, 48, 44 | -2.741 ± 0.6444 | -2.675 ± 0.7012 | -2.825 ± 0.7458 | -2.765 ± 0.7035 |
| Week 72, n=51, 47, 48, 44 | -2.742 ± 0.6453 | -2.622 ± 0.8052 | -2.860 ± 0.6930 | -2.757 ± 0.7094 |
| Week 84, n=51, 47, 47, 43 | -2.725 ± 0.6506 | -2.670 ± 0.7064 | -2.855 ± 0.6923 | -2.743 ± 0.7321 |
| Week 96, n=48, 44, 46, 39 | -2.728 ± 0.6494 | -2.680 ± 0.7116 | -2.854 ± 0.7061 | -2.807 ± 0.7238 |
Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT-E Population.
| Cells per cubic millimeter | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Week 1, n=53, 50, 48, 50 | 85.0 (18.0 to 134.0) | 94.5 (40.0 to 160.0) | 75.5 (18.5 to 129.5) | 42.5 (-23.0 to 111.0) |
| Week 2, n=53, 50, 50, 47 | 75.0 (37.0 to 124.0) | 79.0 (27.0 to 138.0) | 99.5 (53.0 to 160.0) | 55.0 (-10.0 to 132.0) |
| Week 4, n=53, 50, 50, 45 | 75.0 (34.0 to 151.0) | 89.0 (36.0 to 165.0) | 110.0 (46.0 to 170.0) | 89.0 (30.0 to 165.0) |
| Week 8, n=52, 50, 49, 44 | 118.5 (65.5 to 210.5) | 156.5 (93.0 to 226.0) | 129.0 (105.0 to 201.0) | 104.5 (34.5 to 240.5) |
| Week 12, n=53, 48, 48, 45 | 139.0 (96.0 to 284.0) | 137.5 (61.0 to 250.0) | 171.5 (107.5 to 269.0) | 127.0 (58.0 to 186.0) |
| Week 16, n=52, 49, 49, 44 | 153.0 (95.0 to 276.0) | 176.0 (86.0 to 227.0) | 160.0 (94.0 to 227.0) | 115.5 (65.5 to 226.0) |
| Week 20, n=52, 48, 49, 44 | 163.5 (79.5 to 288.5) | 200.0 (103.0 to 316.5) | 139.0 (64.0 to 238.0) | 136.0 (54.5 to 215.5) |
| Week 24, n=51, 49, 47, 44 | 159.0 (97.0 to 233.0) | 206.0 (102.0 to 289.0) | 167.0 (125.0 to 268.0) | 109.5 (66.0 to 229.0) |
| Week 32, n=50, 48, 47, 44 | 221.5 (94.0 to 300.0) | 195.5 (109.0 to 294.0) | 203.0 (125.0 to 282.0) | 146.5 (82.5 to 223.5) |
| Week 40, n=50, 48, 47, 44 | 205.0 (136.0 to 364.0) | 204.5 (157.5 to 346.5) | 224.0 (123.0 to 322.0) | 171.5 (123.0 to 268.0) |
| Week 48, n=51, 47, 47, 45 | 204.0 (127.0 to 384.0) | 249.0 (143.0 to 416.0) | 223.0 (141.0 to 292.0) | 174.0 (91.0 to 292.0) |
| Week 60, n=51, 48, 47, 43 | 265.0 (173.0 to 365.0) | 278.0 (198.5 to 369.5) | 229.0 (166.0 to 306.0) | 221.0 (153.0 to 355.0) |
| Week 72, n=51, 47, 48, 44 | 236.0 (177.0 to 351.0) | 285.0 (186.0 to 427.0) | 220.0 (146.0 to 373.0) | 195.0 (144.0 to 334.5) |
| Week 84, n=51, 47, 46, 42 | 292.0 (222.0 to 408.0) | 313.0 (244.0 to 366.0) | 280.0 (197.0 to 379.0) | 296.5 (187.0 to 400.0) |
| Week 96, n=48, 44, 46, 39 | 335.0 (253.5 to 478.5) | 391.5 (243.0 to 527.0) | 326.0 (236.0 to 451.0) | 301.0 (204.0 to 445.0) |
HIV-associated conditions were assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the acquired immunodeficiency syndrome (AIDS) surveillance case definition.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Category B | 2 | 0 | 1 | 1 |
| Category C | 0 | 0 | 1 | 0 |
| Death | 1 | 0 | 0 | 0 |
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CAT A at Baseline (BS) to CAT B event (EV), CAT A at BS to a CAT C EV; CAT B at BS to a CAT C EV; CAT C at BS to a new CAT C EV; or CAT A, B, or C at BS to death.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| CAT A at Baseline to a CAT C event | 0 | 0 | 0 | 0 |
| CAT B at Baseline to a CAT C event | 0 | 0 | 1 | 0 |
| CAT C at Baseline to a new CAT C event | 0 | 0 | 0 | 0 |
| CAT A, B, or C at Baseline to death | 1 | 0 | 0 | 0 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Baseline | 0 | 0 | 0 | 0 |
| Week 1 | 6 | 4 | 4 | 3 |
| Week 2 | 22 | 19 | 11 | 6 |
| Week 4 | 37 | 35 | 31 | 9 |
| Week 8 | 46 | 45 | 43 | 18 |
| Week 12 | 50 | 46 | 45 | 25 |
| Week 16 | 51 | 46 | 47 | 29 |
| Week 20 | 51 | 47 | 47 | 38 |
| Week 24 | 51 | 46 | 47 | 41 |
| Week 32 | 50 | 45 | 46 | 43 |
| Week 40 | 49 | 45 | 46 | 42 |
| Week 48 | 48 | 45 | 46 | 40 |
| Week 60 | 48 | 44 | 46 | 41 |
| Week 72 | 48 | 44 | 45 | 40 |
| Week 84 | 47 | 43 | 46 | 38 |
| Week 96 | 42 | 40 | 45 | 36 |
Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (\<400 c/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Baseline | 0 | 0 | 0 | 0 |
| Week 1 | 25 | 20 | 16 | 15 |
| Week 2 | 45 | 45 | 41 | 23 |
| Week 4 | 52 | 49 | 48 | 32 |
| Week 8 | 52 | 49 | 49 | 41 |
| Week 12 | 52 | 49 | 49 | 45 |
| Week 16 | 52 | 48 | 49 | 45 |
| Week 20 | 52 | 48 | 49 | 45 |
| Week 24 | 52 | 47 | 48 | 45 |
| Week 32 | 52 | 47 | 48 | 45 |
| Week 40 | 50 | 47 | 48 | 45 |
| Week 48 | 50 | 47 | 48 | 44 |
| Week 60 | 50 | 46 | 48 | 44 |
| Week 72 | 50 | 46 | 47 | 43 |
| Week 84 | 50 | 45 | 47 | 42 |
| Week 96 | 46 | 43 | 46 | 39 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. All clinically suspected cases of hypersensitivity reaction to abacavir in participants receiving abacavir/lamivudine were reported as SAEs. Medical or scientific judgment was to have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold \>=3%) and SAEs.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Any AE | 50 | 46 | 46 | 46 |
| Any SAE | 5 | 5 | 7 | 7 |
Blood samples were collected for the measurement of clinical chemistry and hematology parameters. Toxicities were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Alanine amino transferase | 7 | 11 | 3 | 19 |
| Cholesterol | 18 | 16 | 13 | 24 |
| Creatinine kinase | 17 | 6 | 7 | 5 |
| Lipase | 11 | 13 | 11 | 9 |
| Triglycerides | 0 | 1 | 2 | 1 |
| Alkaline phosphatase | 1 | 0 | 1 | 10 |
| Amylase | 2 | 3 | 1 | 4 |
| Aspartate amino transferase | 12 | 8 | 6 | 9 |
| Carbon dioxide content/bicarbonate | 28 | 24 | 23 | 30 |
| Creatinine | 0 | 4 | 0 | 0 |
| Hypercalcemia | 0 | 0 | 0 | 1 |
| Hyperglycaemia | 16 | 15 | 17 | 17 |
| Hyperkalemia | 0 | 0 | 1 | 1 |
| Hypernatremia | 1 | 1 | 1 | 0 |
| Hypocalcemia | 4 | 5 | 5 | 8 |
| Hypoglycaemia | 3 | 3 | 5 | 4 |
| Hypokalemia | 4 | 1 | 3 | 3 |
| Hyponatremia | 6 | 12 | 7 | 13 |
| Low-density lipoprotein cholesterol | 14 | 15 | 11 | 20 |
| Magnesium | 7 | 6 | 5 | 4 |
| Phosphate, inorganic | 9 | 15 | 14 | 11 |
| Total bilirubin | 3 | 4 | 3 | 0 |
| Activated partial thromboplastin time | 7 | 12 | 6 | 5 |
| Hemoglobin | 0 | 1 | 0 | 1 |
| International normalized ratio | 6 | 9 | 6 | 5 |
| Platelet count | 1 | 4 | 1 | 1 |
| Prothrombin time | 7 | 8 | 7 | 4 |
| Total neutrophils | 9 | 7 | 6 | 10 |
| White blood cell count | 1 | 1 | 1 | 1 |
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Genotypic Resistance Population: all participants in the ITT-E Population with available on-treatment genotypic data, excluding participants who were not protocol-defined virologic failures.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| A23A/V | 1 | 0 | — | 0 |
| S255N | 1 | 0 | — | 0 |
For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Number of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance | 1 | 0 | — | 0 |
The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. Fold increase in DTG FC at the time of PDVF was derived as the PDVF FC/Baseline FC ratio. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 without evidence of prior suppression to \<400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value \>=400 copies/mL.On-treatment Phenotypic Resistance Population: all participants in the ITT-E Population with available on-treatment phenotypic data
| Participants | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| <1 fold | 0 | 1 | — | — |
| 1-<2 fold | 2 | 0 | — | — |
| 2-<4 fold | 0 | 0 | — | — |
| 4-<8 fold | 0 | 0 | — | — |
| >=8 fold | 0 | 0 | — | — |
Blood samples for the determination of plasma DTG concentration were collected from the participants randomized to receive DTG, at the following time points: pre-dose and 2-4 hours post-dose at Weeks 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. The Pharmacokinetic (PK) Summary Population is comprised of all participants who received DTG and underwent intensive PK sampling or limited PK sampling during the study and provided evaluable DTG PK parameters. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles).Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.
| Micrograms per milliliter (µg/mL) | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Week 2, Pre-dose, n=46, 44, 43, 0 | 0.3580 ± 0.18321 | 0.6779 ± 0.44085 | 1.4044 ± 0.88041 | — |
| Week 2, 2-4 hours post-dose, n=31, 29, 29, 0 | 1.0121 ± 0.28125 | 1.9716 ± 0.71890 | 3.8414 ± 1.87405 | — |
| Week 12, Pre-dose, n= 46, 45, 44, 0 | 0.3648 ± 0.16791 | 0.5759 ± 0.32645 | 1.4169 ± 1.00152 | — |
| Week 12, 2-4 hours post-dose, n=48, 45, 45, 0 | 1.0374 ± 0.27517 | 1.7907 ± 0.70953 | 3.6056 ± 1.33862 | — |
| Week 24, Pre-dose, n=45, 44, 44, 0 | 0.3766 ± 0.23399 | 0.6636 ± 0.50767 | 1.4534 ± 0.94283 | — |
| Week 24, 2-4 hours post-dose, n=45, 45, 45, 0 | 1.0113 ± 0.34083 | 1.9021 ± 0.79430 | 3.5397 ± 1.36538 | — |
The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed.
| Hours*µg/mL | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| AUC(0-tau) of DTG | 16.0 ± 40 | 23.1 ± 48 | 48.1 ± 40 | — |
The Cmax, Cmax, and Ctau of DTG were determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.
| µg/mL | DTG 10 mg OD | DTG 25 mg OD | DTG 50 mg OD | EFV 600 mg OD |
|---|---|---|---|---|
| Cmax | 1.10 ± 37 | 1.71 ± 43 | 3.40 ± 27 | — |
| Cmin | 0.33 ± 64 | 0.44 ± 68 | 0.94 ± 74 | — |
| Ctau | 0.37 ± 55 | 0.45 ± 71 | 1.05 ± 72 | — |
The plasma DTG C0 of DTG was determined using limited/sparse PK sampling at Week 2, Week 12, and Week 24. C0 avg was calculated at Week 24 as the mean of the C0 of DTG at Week 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.
| Microgram per milliliter (µg/mL) | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| C0, Week 2, n=46, 44, 43, 0 | 0.31 ± 58 | 0.57 ± 62 | 1.20 ± 61 | — |
| C0, Week 12, n=46, 45, 44, 0 | 0.33 ± 49 | 0.47 ± 77 | 1.13 ± 95 | — |
| C0, Week 24, n=45, 44, 44, 0 | 0.33 ± 67 | 0.57 ± 74 | 1.20 ± 74 | — |
| C0 avg, n=48, 46, 46, 0 | 0.34 ± 49 | 0.56 ± 61 | 1.25 ± 55 | — |
Tmax of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.
| Hours | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD |
|---|---|---|---|---|
| Time to Maximal Drug Concentration (Tmax) of DTG | 2.0 (2.0 to 4.0) | 2.0 (2.0 to 8.0) | 2.0 (1.9 to 4.0) | — |
Relationships between Week 2 plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in plasma HIV-1 RNA at Week 2 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between plasma HIV-1 RNA and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. PK/Pharmacodynamic (PD) Analysis Population: all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable DTG plasma concentration data considered suitable for investigation of relationship with the PD measures
| Pearson's correlation coefficient | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Overall DTG |
|---|---|---|---|---|---|
| AUC(0-tau) | 0.426 | -0.018 | -0.258 | — | -0.086 |
| Cmax | 0.452 | -0.051 | -0.150 | — | -0.055 |
| Ctau | 0.273 | -0.100 | -0.263 | — | -0.129 |
Relationships between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], C0avg \[average pre-dose concentration\], and Ctau \[concentration at the end of the dosing interval\]) and the change from Baseline in CD4+ cell counts at Week 96 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between CD4+ cell counts and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association.Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.Only those participants available at the specified time points were analyzed (represented by n=X in the category titles)
| Pearson's correlation coefficient | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Overall DTG |
|---|---|---|---|---|---|
| AUC(0-tau), n=13, 14, 15, 0 | -0.100 | 0.379 | 0.008 | — | -0.005 |
| Cmax, n=13, 14, 15, 0 | -0.047 | 0.332 | 0.234 | — | 0.037 |
| C0avg, n=43, 40, 42, 0 | -0.009 | -0.013 | 0.206 | — | -0.011 |
| Ctau, n=13, 14, 15, 0 | -0.289 | 0.299 | -0.074 | — | -0.055 |
Relationships between log-transformed plasma DTG PK parameters (AUC\[0-tau\], Cmax, C0, C0avg, Ctau, and Cmin) and safety parameters (AE occurrence, maximum AE intensity, alanine aminotransferase \[ALT\], change from Baseline \[CFB\] in ALT, total bilirubin, CFB in total bilirubin, creatine kinase, CFB in creatine kinase, triglycerides, CFB in triglycerides, lipase, CFB in lipase, total cholesterol \[TC\], CFB in TC) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between safety parameters and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. The presence of \>=1 AE was used for AE occurrence. The most severe AE grade/intensity was used for maximum AE intensity. Maximum laboratory values per participant were used for safety parameters. CFB was calculated as the post-Baseline value minus the value at Baseline.
| Pearson's correlation coefficient | Overall DTG |
|---|---|
| AUC(0-tau) versus AE occurrence, n=45 | 0.114 |
| AUC(0-tau) versus maximum AE intensity, n=45 | 0.171 |
| AUC(0-tau) versus ALT, n=45 | -0.196 |
| AUC(0-tau) versus CFB in ALT, n=45 | -0.201 |
| AUC(0-tau) versus total bilirubin, n=45 | 0.364 |
| AUC(0-tau) versus CFB in total bilirubin, n=45 | 0.147 |
| AUC(0-tau) versus creatine kinase, n=45 | -0.168 |
| AUC(0-tau) versus CFB in creatine kinase, n=45 | -0.145 |
| AUC(0-tau) vs Triglycerides, n=45 | 0.104 |
| AUC(0-tau) versus CFB in triglycerides, n=45 | 0.216 |
| AUC(0-tau) versus lipase, n=45 | -0.066 |
| AUC(0-tau) versus CFB in lipase, n=45 | 0.092 |
| AUC(0-tau) versus total cholesterol, n=45 | -0.097 |
| AUC(0-tau) versus CFB in total cholesterol, n=45 | -0.153 |
| Cmax versus AE occurrence, n=45 | 0.061 |
| Cmax versus maximum AE intensity, n=45 | 0.110 |
| Cmax versus ALT, n=45 | -0.135 |
| Cmax versus CFB in ALT, n=45 | -0.135 |
| Cmax versus total bilirubin, n=45 | 0.265 |
| Cmax versus CFB in total bilirubin, n=45 | 0.033 |
| Cmax versus creatine kinase, n=45 | -0.188 |
| Cmax versus CFB in creatine kinase, n=45 | -0.161 |
| Cmax versus triglycerides, n=45 | 0.134 |
| Cmax versus CFB in triglycerides, n=45 | 0.244 |
| Cmax versus lipase, n=45 | -0.034 |
| Cmax versus CFB in lipase, n=45 | 0.115 |
| Cmax versus total cholesterol, n=45 | -0.101 |
| Cmax versus CFB in total cholesterol, n=45 | -0.192 |
| C0 versus AE occurrence, n=133 | -0.080 |
| C0 versus maximum AE intensity, n=133 | -0.003 |
| C0 versus ALT, n=133 | -0.196 |
| C0 versus CFB in ALT, n=133 | -0.237 |
| C0 versus total bilirubin, n=133 | 0.298 |
| C0 versus CFB in total bilirubin, n=133 | 0.120 |
| C0 versus creatine kinase, n=133 | -0.094 |
| C0 versus CFB in creatine kinase, n=133 | -0.093 |
| C0 versus triglycerides, n=133 | -0.058 |
| C0 versus CFB in triglycerides, n=133 | -0.012 |
| C0 versus lipase, n=133 | -0.187 |
| C0 versus CFB in lipase, n=133 | -0.137 |
| C0 versus total cholesterol, n=133 | -0.179 |
| C0 versus CFB in total cholesterol, n=133 | -0.125 |
| C0avg versus AE occurrence, n=140 | -0.028 |
| C0avg versus maximum AE intensity, n=140 | 0.036 |
| C0avg versus ALT, n=140 | -0.166 |
| C0avg versus CFB in ALT, n=140 | -0.177 |
| C0avg versus total bilirubin, n=140 | 0.319 |
| C0avg versus CFB in total bilirubin, n=140 | 0.109 |
| C0avg versus creatine kinase, n=140 | -0.114 |
| C0avg versus CFB in creatine kinase, n=140 | -0.110 |
| C0avg versus triglycerides, n=140 | 0.057 |
| C0avg versus CFB in triglycerides, n=140 | 0.092 |
| C0avg versus lipase, n=140 | -0.164 |
| C0avg versus CFB in lipase, n=140 | -0.120 |
| C0avg versus total cholesterol, n=140 | -0.170 |
| C0avg versus CFB in total cholesterol, n=140 | -0.083 |
| Ctau versus AE occurrence, n=45 | 0.190 |
| Ctau versus maximum AE intensity, n=45 | 0.205 |
| Ctau versus ALT, n=45 | -0.281 |
| Ctau versus CFB in ALT, n=45 | -0.285 |
| Ctau versus total bilirubin, n=45 | 0.446 |
| Ctau versus CFB in total bilirubin, n=45 | 0.237 |
| Ctau versus creatine kinase, n=45 | -0.143 |
| Ctau versus CFB in creatine kinase, n=45 | -0.125 |
| Ctau versus triglycerides, n=45 | 0.061 |
| Ctau versus CFB in triglycerides, n=45 | 0.172 |
| Ctau versus lipase, n=45 | -0.131 |
| Ctau versus CFB in lipase, n=45 | 0.056 |
| Ctau versus total cholesterol, n=45 | -0.039 |
| Ctau versus CFB in total cholesterol, n=45 | -0.108 |
| Cmin versus AE occurrence, n=45 | 0.156 |
| Cmin versus maximum AE intensity, n=45 | 0.193 |
| Cmin versus ALT, n=45 | -0.236 |
| Cmin versus CFB in ALT, n=45 | -0.253 |
| Cmin versus total bilirubin, n=45 | 0.430 |
| Cmin versus CFB in total bilirubin, n=45 | 0.171 |
| Cmin versus creatine kinase, n=45 | -0.132 |
| Cmin versus CFB in creatine kinase, n=45 | -0.124 |
| Cmin versus triglycerides, n=45 | -0.042 |
| Cmin versus CFB in triglycerides, n=45 | 0.057 |
| Cmin versus lipase, n=45 | -0.135 |
| Cmin versus CFB in lipase, n=45 | 0.032 |
| Cmin versus total cholesterol, n=45 | -0.194 |
| Cmin versus CFB in total cholesterol, n=45 | -0.208 |
Logistic regressions were performed to examine the correlation between plasma DTG PK parameters (AUC\[0-tau\] \[area under the time concentration curve over the dosing interval\], Cmax \[maximal concentration\], Ctau \[concentration at the end of the dosing interval\], and C0avg \[average pre-dose concentration\]) on log scales and the presence of gastrointestinal system organ class AEs (abdominal pain, diarrhea, nausea, and vomiting) at Week 96. Data are presented as estimates from logistic regression, which is a measure of the association between AEs of special interest and plasma DTG PK parameters. A value of 0 indicates no statistical association; a large absolute value of the estimate indicates higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Results are presented for participants in any DTG group (overall DTG).Only those participants available at the specified time points were analyzed represented by n=X in the category titles
| estimated effect | Overall DTG |
|---|---|
| Abdominal pain versus AUC(0-tau), n=45 | -2.49 |
| Abdominal pain versus Cmax, n=45 | -2.98 |
| Abdominal pain versus Ctau, n=45 | -1.72 |
| Abdominal pain versus C0avg, n=140 | -0.41 |
| Diarrhoea versus AUC(0-tau), n=45 | -0.62 |
| Diarrhoea versus Cmax, n=45 | -0.98 |
| Diarrhoea versus Ctau, n=45 | -0.29 |
| Diarrhoea versus C0avg, n=140 | 0.13 |
| Nausea versus AUC(0-tau), n=45 | -0.31 |
| Nausea versus Cmax, n=45 | -0.72 |
| Nausea versus Ctau, n=45 | 0.03 |
| Nausea versus C0avg, n=140 | -0.32 |
| Vomiting versus AUC(0-tau), n=45 | -1.29 |
| Vomiting versus Cmax, n=45 | -1.61 |
| Vomiting versus Ctau, n=45 | -1.15 |
| Vomiting versus C0avg, n=140 | -0.89 |
Change from Baseline in CD8+ cell count data are not available; CD8+ data are only listed on a per-participant basis and were not summarized.
No measurements were reported for this outcome.
Collected over Serious adverse events (SAEs) and non-serious AEs were collected in the time period from Baseline up to end of study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG 10mg QD | 2/53 (3.8%) | 6/53 (11.3%) | 49/53 (92.5%) |
| DTG 25mg QD | 0/51 (0%) | 4/51 (7.8%) | 46/51 (90.2%) |
| DTG 50mg QD | 0/51 (0%) | 7/51 (13.7%) | 45/51 (88.2%) |
| EFV 600mg | 0/50 (0%) | 7/50 (14%) | 46/50 (92%) |
| Open-label DTG 50 mg QD | 2/138 (1.4%) | 16/138 (11.6%) | 112/138 (81.2%) |
| Event | DTG 10mg QD | DTG 25mg QD | DTG 50mg QD | EFV 600mg | Open-label DTG 50 mg QD |
|---|---|---|---|---|---|
| Device malfunctionProduct Issues | 0/53 | 0/51 | 0/51 | 1/50 | 1/138 |
| BronchitisInfections and infestations | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| DepressionPsychiatric disorders | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| EpididymitisInfections and infestations | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| GastroenteritisInfections and infestations | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| HydrocephalusNervous system disorders | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| NeurosyphilisInfections and infestations | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| Suicide attemptPsychiatric disorders | 0/53 | 0/51 | 0/51 | 1/50 | 0/138 |
| PneumoniaInfections and infestations | 0/53 | 0/51 | 1/51 | 0/50 | 1/138 |
| Wrist fractureInjury, poisoning and procedural complications | 0/53 | 0/51 | 1/51 | 0/50 | 1/138 |
| Event | DTG 10mg QD | DTG 25mg QD | DTG 50mg QD | EFV 600mg | Open-label DTG 50 mg QD |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 2/53 | 3/51 | 3/51 | 11/50 | 2/138 |
| NauseaGastrointestinal disorders | 10/53 | 8/51 | 6/51 | 7/50 | 2/138 |
| DiarrhoeaGastrointestinal disorders | 6/53 | 9/51 | 7/51 | 5/50 | 12/138 |
| HeadacheNervous system disorders | 7/53 | 6/51 | 8/51 | 3/50 | 8/138 |
| Viral upper respiratory tract infectionInfections and infestations | 7/53 | 7/51 | 6/51 | 5/50 | 20/138 |
| InsomniaPsychiatric disorders | 0/53 | 7/51 | 6/51 | 6/50 | 5/138 |
| RashSkin and subcutaneous tissue disorders | 5/53 | 3/51 | 2/51 | 6/50 | 2/138 |
| FatigueGeneral disorders | 2/53 | 4/51 | 2/51 | 6/50 | 3/138 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/53 | 4/51 | 6/51 | 2/50 | 10/138 |
| DepressionPsychiatric disorders | 3/53 | 6/51 | 2/51 | 5/50 | 6/138 |
| Age, Continuous(Years) | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 34.2 ± 9.25 | 37.0 ± 9.79 | 37.0 ± 8.89 | 40.7 ± 11.19 | 37.2 ± 10.00 |
| Sex: Female, Male(Participants) | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Total |
|---|---|---|---|---|---|
| Female | 11 | 5 | 6 | 6 | 28 |
| Male | 42 | 46 | 45 | 44 | 177 |
| Race/Ethnicity, Customized(participants) | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD | EFV 600 mg QD | Total |
|---|---|---|---|---|---|
| African American/African Heritage (HER) | 7 | 6 | 8 | 4 | 25 |
| American Indian or Alaska Native | 1 | 3 | 4 | 2 | 10 |
| Japanese/East Asian HER/South East Asian HER | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or other Pacific Islander | 3 | 0 | 0 | 0 | 3 |
| White | 41 | 42 | 38 | 43 | 164 |
| African American/African HER & White | 0 | 0 | 1 | 0 | 1 |
| Asian & White | 1 | 0 | 0 | 0 | 1 |
The record gives a start of Jul 2009, a primary completion of Feb 2010 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 3 years 8 months after primary completion. A results delay was requested in Mar 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir